Lung and breast cancer therapies have seen remarkable advances, from curative treatments and novel targeted agents to innovative immunotherapeutic strategies. The optimal implementation of a multidisciplinary strategy, whether as standard care or within clinical trials, is essential for improving outcomes across multiple lines of care.